Compare Nokia Corp (NOK) vs Pfizer Inc (PFE) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Nokia Corp vs Pfizer Inc — how do they compare? Nokia Corp trades at $10.36 (market cap $56.99B), while Pfizer Inc trades at $28.27 (market cap $158.56B). The key difference: Pfizer Inc is far larger — about 2.8× Nokia Corp's market cap, and Pfizer Inc pays the higher dividend (6.18%). Which is the better fit depends on your goals — on Pluang, investors hold Nokia Corp for 66 Days and Pfizer Inc for 158 Days on average.
| NOK | PFE | |
|---|---|---|
Market Cap | $56.99B | $158.56B |
Volume | 69,968,204 | 44,138,282 |
Sector | Technology | Health |
52-Week High | $16.83 | $29.02 |
52-Week Low | $5.18 | $23.67 |
Typical Hold Time | 66 Days | 158 Days |
Enterprise Value | $55.01B | $210.06B |
Dividend Yield | 1.61% | 6.18% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Nokia (NOK) trades at $10.36, down 2.45% on the day, with a bearish technical signal and neutral oscillators. The company reported mixed quarterly earnings, with a beat in Q2 2026 but a miss in Q1 2026. Revenue for 2025 was $19.89 billion, with a net income margin of 3.47%. Recent news highlights partnerships in AI and satellite communications, including an expanded collaboration with Microsoft and a defense-focused satellite venture with ICEYE.
The stock presents a valuation disconnect, with a high P/E of 75.09 but strong analyst optimism—61.5% recommend Buy, with a consensus price target of $17.50. Upside catalysts include AI infrastructure demand and strategic partnerships, while risks involve competitive pressures and volatile cash flows, evidenced by a net cash outflow of $1.16 billion in 2025.
Pfizer (PFE) trades at $28.00, up 1.87% on the day, with a bullish technical signal from moving averages. The company reported revenue of $62.58 billion in 2025 with a net income margin of 6.8%, and has beaten EPS estimates for the last three quarters. Recent news highlights Pfizer's focus on its obesity and oncology pipeline as key growth drivers in 2026.
The stock presents a value opportunity with a consensus price target of $29.17, but faces risks from patent expirations and projected earnings decline. Investor sentiment is mixed, with analysts largely neutral, emphasizing the stock's defensive cash flow and dividend yield amid ongoing business transformation.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Nokia Corp
Nokia is a leading vendor in the telecommunications equipment industry. The company's network business derives revenue from selling wireless and fixed-line hardware, software, and services. Nokia's technology segment licenses its patent portfolio to handset manufacturers and makes royalties from Nokia-branded cellphones. The company, headquartered in Espoo, Finland, operates on a global scale, with most of its revenue from communication service providers.
Read more on NOK →About Pfizer Inc
Pfizer Inc. operates as a pharmaceutical company. The Company offers medicines, vaccines, medical devices, and consumer healthcare products for oncology, inflammation, cardiovascular, and other therapeutic areas. Pfizer serves customers worldwide.
Read more on PFE →
